$11.85
-0.075-0.63%
Last update: Nov 11, 10:15 AM
Zevra Therapeutics Inc
ZVRANASDAQ
Zevra Therapeutics rose 26.4% from $9.43 to $11.92, ahead of the S&P 500's +9.8%. Its worst day was Jul 24 (−23.9%), and its low came Dec 18 at $8.10.
Nov 11, 2025 – Nov 10, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Zevra Therapeutics closed at its lowest level of the year, 14.1% below where the year started.
−0.1% · S&P 500 +0.5%
Story events cover the past 12 months · Times ET
EPS of $0.19 beat the $0.05 estimate on $34.1M revenue (est. $28.0M).
+21.3%, the year's best day, on 9M shares, the year's heaviest volume · S&P 500 −0.2%
EPS of $0.18 beat the $0.08 estimate on $36.2M revenue (est. $31.8M).
−2.2% · S&P 500 −0.3%
MIPLYFFA patent submitted for Orange Book listing, with patent protection to 2041Separately filed patent term extension remains pending with the U.S.
+13.9% · S&P 500 +0.2%
Zevra Therapeutics closed at its highest level of the year, 56.4% above where the year started.
+2.1% · S&P 500 −0.3%
Under European regulatory procedures, the Company plans to request a re-examination of the CHMP opinion and submit a detailed explanation outlining the basis for the request."While the review did not result in the
−23.9%, the year's worst day · S&P 500 +0.1%
EPS of $0.25 beat the $0.14 estimate on $39.7M revenue (est. $33.6M).
+12.8% · S&P 500 −0.2%
EPS of $0.18 beat the $0.17 estimate on $37.8M revenue (est. $37.3M).
+8.9% · S&P 500 +1.7%
Where it ended: a close of $11.92 on Nov 10, 2026. Up next: Q4 2026 earnings on Mar 8, 2027 (EPS est. $0.17, revenue est. $40.3M).
Nothing in the past 12 months.
All ZVRA dividend historyReplay the year: the line draws itself and stops at each of the 8 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for ZVRA and SPY from Benzinga historical bars. Not investment advice.
